← Shanghai Haoyuan Chemexpress Co. Ltd. A overview

Shanghai Haoyuan Chemexpress Co. Ltd. A vs Jiangsu Hengrui Medicine: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai Haoyuan Chemexpress Co. Ltd. A (688131.CG)

Q3 2026
▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

  • FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.

    A concrete regulatory milestone that expands the addressable market and supports future earnings.

  • First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.

    The half-year results are the clearest evidence of the company's underlying earnings trend.

  • Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.

    Dividend policy is a direct signal of financial health and shareholder returns.

  • 15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.

    Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

August 2026
▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

  • FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.

    A concrete regulatory milestone that expands the addressable market and supports future earnings.

  • First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.

    The half-year results are the clearest evidence of the company's underlying earnings trend.

  • Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.

    Dividend policy is a direct signal of financial health and shareholder returns.

  • 15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.

    Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

Latest
▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

  • FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.

    A concrete regulatory milestone that expands the addressable market and supports future earnings.

  • First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.

    The half-year results are the clearest evidence of the company's underlying earnings trend.

  • Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.

    Dividend policy is a direct signal of financial health and shareholder returns.

  • 15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.

    Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

Jiangsu Hengrui Medicine Co Ltd (600276.CG)

Q3 2026
▲3

Hengrui's global licensing deals and pipeline progress drove Q3 gains

  • Major global licensing deals Hengrui signed a $2.6bn obesity drug deal with Novo Nordisk and a GSK alliance worth up to $12bn, validating its pipeline and bringing in significant cash.

    These deals are a key new driver of the stock's momentum this quarter.

  • Pipeline and regulatory progress Positive Phase 3 results for oral GLP-1 HRS-7535, new drug approvals, and ten anti-tumor drugs entering clinical trials showed strong pipeline advancement.

    Pipeline milestones are a core reason for investor optimism this period.

  • Shift to innovative drugs Innovative drugs now exceed 60% of revenue, reflecting Hengrui's successful transformation and supporting higher growth prospects.

    This strategic shift underpins the company's improving business mix and valuation.

  • Buyback and competitive pressure A 1–2bn yuan buyback signaled management confidence, but competition in children's myopia drugs from Qilu Pharmaceutical could pressure Hengrui subsidiary Shengdi's market share.

    This captures both a positive confidence signal and a real competitive risk.

September 2026
▲4

Hengrui's obesity drug deal with Novo Nordisk headlines a wave of new licensing and pipeline wins

  • Novo Nordisk licenses Hengrui obesity drug in $2.6bn deal Hengrui licensed its experimental obesity and diabetes drug HRS-1596 to Novo Nordisk for up to $2.6 billion, including $300 million upfront plus future milestone payments and royalties. This validates Hengrui's pipeline and brings immediate cash, supporting the share price.

    This is the biggest new event of the period and directly boosts Hengrui's value through a major licensing deal.

  • Ten anti-tumor drugs approved for clinical trials China's drug regulator approved clinical trials for 10 of Hengrui's anti-tumor drugs, with cumulative R&D investment of 3.2 billion yuan. This advances Hengrui's pipeline and shows progress in innovative cancer treatments, which can lift future revenue expectations.

    This is a new pipeline milestone that adds to Hengrui's growth story and supports the stock.

  • GSK alliance worth up to $12bn highlights Hengrui's global appeal GSK formed an alliance with Hengrui worth up to $12 billion, part of a broader trend of Western drugmakers partnering with Chinese biotech. This reinforces Hengrui's ability to attract big licensing deals, supporting its long-term revenue and share price.

    This new partnership news underscores Hengrui's growing global relevance and licensing demand.

  • Hengrui starts share buyback Hengrui repurchased 335,000 A-shares for 14.5 million yuan, beginning its previously announced buyback plan. Buying back shares reduces the number outstanding and signals management's confidence, which can support the stock price.

    This is a new capital action that shows management's confidence and can lift the share price.

Latest
▲4

Hengrui's obesity drug deal with Novo Nordisk headlines a wave of new licensing and pipeline wins

  • Novo Nordisk licenses Hengrui obesity drug in $2.6bn deal Hengrui licensed its experimental obesity and diabetes drug HRS-1596 to Novo Nordisk for up to $2.6 billion, including $300 million upfront plus future milestone payments and royalties. This validates Hengrui's pipeline and brings immediate cash, supporting the share price.

    This is the biggest new event of the period and directly boosts Hengrui's value through a major licensing deal.

  • Ten anti-tumor drugs approved for clinical trials China's drug regulator approved clinical trials for 10 of Hengrui's anti-tumor drugs, with cumulative R&D investment of 3.2 billion yuan. This advances Hengrui's pipeline and shows progress in innovative cancer treatments, which can lift future revenue expectations.

    This is a new pipeline milestone that adds to Hengrui's growth story and supports the stock.

  • GSK alliance worth up to $12bn highlights Hengrui's global appeal GSK formed an alliance with Hengrui worth up to $12 billion, part of a broader trend of Western drugmakers partnering with Chinese biotech. This reinforces Hengrui's ability to attract big licensing deals, supporting its long-term revenue and share price.

    This new partnership news underscores Hengrui's growing global relevance and licensing demand.

  • Hengrui starts share buyback Hengrui repurchased 335,000 A-shares for 14.5 million yuan, beginning its previously announced buyback plan. Buying back shares reduces the number outstanding and signals management's confidence, which can support the stock price.

    This is a new capital action that shows management's confidence and can lift the share price.

August 2026
▲4

Hengrui's pipeline and buyback drive value as China biotech gains

  • China's drug development rise boosts Hengrui's licensing appeal China has overtaken the US in clinical drug development, with a third of Big Pharma's licensed drugs now from Chinese labs. Hengrui's $15.2bn Bristol Myers and $2bn Merck deals show its pipeline is in demand, supporting future revenue and share price.

    This structural shift increases demand for Hengrui's drug candidates and validates its licensing business model.

  • Buyback and employee plan signal confidence Hengrui will spend 1-2 billion yuan buying back A-shares for an employee stock ownership plan. This reduces shares outstanding and shows management believes the stock is undervalued, which can lift the price.

    Buybacks directly affect capital structure and signal insider confidence, a key driver for the stock.

  • Interim results show innovative drug growth First-half revenue fell 1.94% to 15.46bn yuan, but net profit rose 0.34% and innovative drug sales jumped 16.38%, now 63% of drug sales. Non-oncology innovative drugs surged 74%, showing a successful shift to higher-value medicines.

    The earnings report reveals the core profit driver—innovative drugs—which is key to the investment case.

  • Oral GLP-1 application accepted, opening huge market China's regulator accepted Hengrui's marketing application for HRS-7535, an oral GLP-1 for diabetes and weight loss. Positive Phase III results support approval, potentially tapping the fast-growing obesity and diabetes market.

    This is a concrete pipeline milestone that could add a major new revenue stream, directly impacting future earnings.

▲4

Hengrui's pipeline and buyback drive value as China biotech gains

  • China's drug development rise boosts Hengrui's licensing appeal China has overtaken the US in clinical drug development, with a third of Big Pharma's licensed drugs now from Chinese labs. Hengrui's $15.2bn Bristol Myers and $2bn Merck deals show its pipeline is in demand, supporting future revenue and share price.

    This structural shift increases demand for Hengrui's drug candidates and validates its licensing business model.

  • Buyback and employee plan signal confidence Hengrui will spend 1-2 billion yuan buying back A-shares for an employee stock ownership plan. This reduces shares outstanding and shows management believes the stock is undervalued, which can lift the price.

    Buybacks directly affect capital structure and signal insider confidence, a key driver for the stock.

  • Interim results show innovative drug growth First-half revenue fell 1.94% to 15.46bn yuan, but net profit rose 0.34% and innovative drug sales jumped 16.38%, now 63% of drug sales. Non-oncology innovative drugs surged 74%, showing a successful shift to higher-value medicines.

    The earnings report reveals the core profit driver—innovative drugs—which is key to the investment case.

  • Oral GLP-1 application accepted, opening huge market China's regulator accepted Hengrui's marketing application for HRS-7535, an oral GLP-1 for diabetes and weight loss. Positive Phase III results support approval, potentially tapping the fast-growing obesity and diabetes market.

    This is a concrete pipeline milestone that could add a major new revenue stream, directly impacting future earnings.

July 2026
▲3▼1

Hengrui's innovative drug pipeline and global deals drive growth

  • Innovative drugs now over 60% of revenue Hengrui's innovative drug sales exceeded 60% of total revenue for the first time, showing strong demand. This shift from traditional generics to higher-margin innovative drugs supports profit growth and a higher valuation.

    This milestone shows the company's successful transformation and is a key driver of its earnings and stock price.

  • Positive Phase 3 results for oral GLP-1 drug Kailera reported positive Phase 3 results for the oral GLP-1 drug HRS-7535, which Hengrui developed. This validates Hengrui's pipeline and opens a large market for obesity and diabetes, boosting future revenue potential.

    This is a major clinical milestone that de-risks a high-value asset and could lead to significant future sales.

  • New drug approvals and orphan drug designation Hengrui received clinical trial approval for HRS-8797 for atopic dermatitis, FDA orphan drug designation for SHR-4375 for pancreatic cancer, and approval for insulin degludec, China's first long-acting insulin analogue. These expand its product portfolio and market reach.

    These regulatory wins add new growth drivers and demonstrate Hengrui's R&D strength across multiple therapeutic areas.

  • Competition intensifies in children's myopia drug market Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding competition for Hengrui's subsidiary Shengdi, which has a similar product in marketing application. This could pressure future sales and market share.

    This is a real counterweight that could limit upside in one of Hengrui's near-term opportunities.

▲3▼1

Hengrui's innovative drug pipeline and global deals drive growth

  • Innovative drugs now over 60% of revenue Hengrui's innovative drug sales exceeded 60% of total revenue for the first time, showing strong demand. This shift from traditional generics to higher-margin innovative drugs supports profit growth and a higher valuation.

    This milestone shows the company's successful transformation and is a key driver of its earnings and stock price.

  • Positive Phase 3 results for oral GLP-1 drug Kailera reported positive Phase 3 results for the oral GLP-1 drug HRS-7535, which Hengrui developed. This validates Hengrui's pipeline and opens a large market for obesity and diabetes, boosting future revenue potential.

    This is a major clinical milestone that de-risks a high-value asset and could lead to significant future sales.

  • New drug approvals and orphan drug designation Hengrui received clinical trial approval for HRS-8797 for atopic dermatitis, FDA orphan drug designation for SHR-4375 for pancreatic cancer, and approval for insulin degludec, China's first long-acting insulin analogue. These expand its product portfolio and market reach.

    These regulatory wins add new growth drivers and demonstrate Hengrui's R&D strength across multiple therapeutic areas.

  • Competition intensifies in children's myopia drug market Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding competition for Hengrui's subsidiary Shengdi, which has a similar product in marketing application. This could pressure future sales and market share.

    This is a real counterweight that could limit upside in one of Hengrui's near-term opportunities.